

Guidelines for using the QuantiFERON-TB test for diagnosing tuberculosis infection. Centers for Disease Control and Prevention.

MMWR Recommendations and Reports  
52, 15-8

Citation Report

#	ARTICLE	IF	CITATIONS
1	A clinical approach to paediatric tuberculosis in Canada. Paediatrics and Child Health, 2003, 8, 162-170.	0.6	5
2	Specific T-Cell Epitopes for Immunoassay-Based Diagnosis of Mycobacterium tuberculosis Infection. Journal of Clinical Microbiology, 2004, 42, 2379-2387.	3.9	126
3	New Guidelines About Latent Tuberculosis Infection in Children and Adolescents: A Welcome Advancement. Pediatrics, 2004, 114, 1084-1086.	2.1	15
4	Targeted Tuberculin Skin Testing and Treatment of Latent Tuberculosis Infection in Children and Adolescents. Pediatrics, 2004, 114, 1175-1201.	2.1	154
5	Improved Sensitivity of Nucleic Acid Amplification for Rapid Diagnosis of Tuberculous Meningitis. Journal of Clinical Microbiology, 2004, 42, 3036-3040.	3.9	20
6	Evaluation of an In Vitro Assay for Gamma Interferon Production in Response to Mycobacterium tuberculosis Infections. Vaccine Journal, 2004, 11, 1089-1093.	2.6	24
8	Interferon- $\gamma$ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infectious Diseases, The, 2004, 4, 761-776.	9.1	876
9	High risk of Mycobacterium tuberculosis infection during the Hajj pilgrimage. Tropical Medicine and International Health, 2005, 10, 336-339.	2.3	72
10	Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR. Journal of Immunological Methods, 2005, 298, 129-141.	1.4	51
11	Sensitivity of human gamma interferon assay and tuberculin skin testing for detecting infection with Mycobacterium tuberculosis in patients with culture positive tuberculosis. Tuberculosis, 2005, 85, 137-145.	1.9	19
12	Tuberculosis associated with therapy against tumor necrosis factor $\alpha$ . Arthritis and Rheumatism, 2005, 52, 2968-2974.	6.7	110
13	CD69 Expression on CD4 + T Lymphocytes after In Vitro Stimulation with Tuberculin Is an Indicator of Immune Sensitization against Mycobacterium tuberculosis Antigens. Vaccine Journal, 2005, 12, 101-106.	3.1	17
14	Preliminary Evaluation of Whole-Blood Gamma Interferon Release for Clinical Assessment of Cellular Immunity in Patients with Active Coccidioidomycosis. Vaccine Journal, 2005, 12, 700-704.	3.1	11
15	Tuberculosis in health care workers during declining tuberculosis incidence in New York State. American Journal of Infection Control, 2005, 33, 519-526.	2.3	34
16	Prospective Evaluation of a Whole-Blood Test Using <i>Mycobacterium tuberculosis</i> -Specific Antigens ESAT-6 and CFP-10 for Diagnosis of Active Tuberculosis. Vaccine Journal, 2005, 12, 491-496.	3.1	164
17	The Importance of Two-Step Tuberculin Skin Testing for Newly Employed Healthcare Workers. Infection Control and Hospital Epidemiology, 2006, 27, 512-514.	1.8	8
18	High Rate of Negative Results of Tuberculin and QuantiFERON Tests Among Individuals With a History of Positive Skin Test Results. Infection Control and Hospital Epidemiology, 2006, 27, 436-441.	1.8	18
19	Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax, 2006, 61, 616-620.	5.6	163

#	ARTICLE	IF	CITATIONS
20	Pulmonary Adverse Events of Anti-Tumor Necrosis Factor- $\alpha$ Antibody Therapy. American Journal of Medicine, 2006, 119, 639-646.	1.5	58
21	Latent Tuberculous Infection. Disease-a-Month, 2006, 52, 441-445.	1.1	5
22	Diagnosis of latent tuberculosis infection: The potential role of new technologies. Respiratory Medicine, 2006, 100, 2098-2106.	2.9	45
23	Tuberculosis in Children: An Update. Advances in Pediatrics, 2006, 53, 279-322.	1.4	37
24	Posttransplant Mycobacterium Tuberculosis Disease Following Liver Transplantation and the Need for Cautious Evaluation of Quantiferon TB GOLD Results in the Transplant Setting: A Case Report. Transplantation Proceedings, 2006, 38, 1083-1085.	0.6	24
25	Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infectious Diseases, 2006, 6, 47.	2.9	71
26	Case-Control study of Firefighters with documented positive tuberculin skin test results using Quantiferon-TB testing in comparison with Firefighters with negative tuberculin skin test results. Journal of Occupational Medicine and Toxicology, 2006, 1, 28.	2.2	1
27	Time Delay, Temperature Effects and Assessment of Positive Controls on Whole Blood for the Gamma Interferon ELISA to Detect Paratuberculosis. Zoonoses and Public Health, 2006, 53, 213-217.	1.4	12
28	Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. British Journal of Haematology, 2006, 132, 3-12.	2.5	178
29	Advances in tuberculosis vaccine strategies. Nature Reviews Microbiology, 2006, 4, 469-476.	28.6	263
31	Trends in Sunburns, Sun Protection Practices, and Attitudes Toward Sun Exposure Protection and Tanning Among US Adolescents, 1998-2004. Pediatrics, 2006, 118, 853-864.	2.1	136
33	In Vitro Gamma Interferon Tests for the Detection of Tuberculosis Infection. Journal of Immunotoxicology, 2007, 4, 219-224.	1.7	2
34	Humoral response to HspX and GlcB to previous and recent infection by Mycobacterium tuberculosis. BMC Infectious Diseases, 2007, 7, 148.	2.9	22
35	Latent tuberculosis infection in a military setting diagnosed by whole-blood interferon- $\gamma$ assay. Respiriology, 2007, 12, 898-901.	2.3	9
36	Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clinical Immunology, 2007, 123, 235-243.	3.2	13
37	QuantIFERON-TB gold assay for tuberculosis infection. Clinical Microbiology Newsletter, 2007, 29, 129-136.	0.7	4
38	Combined effect of Neridronate and specific antibiotic therapy in a case of tuberculous spondylodiscitis. Rheumatology International, 2008, 28, 495-498.	3.0	4
39	QuantIFERON <sup>®</sup> -TB Gold assay for the diagnosis of latent tuberculosis infection. Expert Review of Molecular Diagnostics, 2008, 8, 247-256.	3.1	28

#	ARTICLE	IF	CITATIONS
40	Update on the Natural History and Systemic Treatment of Psoriasis. <i>Advances in Dermatology</i> , 2008, 24, 171-196.	2.0	33
41	From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 94-105.	1.2	109
42	QuantiFERON-TB Gold and selected region of difference 1 peptide-based assays for the detection of <i>Mycobacterium tuberculosis</i> infection in a cohort of patients enrolled with suspected tuberculosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 62, 395-401.	1.8	6
43	Comparison of the interferon- $\gamma$ release assay and the tuberculin skin test for contact investigation of tuberculosis in BCG-vaccinated health care workers. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 373-380.	1.5	34
44	Post-travel Screening. , 2008, , 505-512.		1
45	Screening of Donor and Recipient Prior to Solid Organ Transplantation. <i>American Journal of Transplantation</i> , 2009, 9, S7-S18.	4.7	153
46	Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors. <i>Clinical Rheumatology</i> , 2009, 28, 167-172.	2.2	28
47	High Prevalence of Latent Tuberculosis Infection in Patients in End-Stage Renal Disease on Hemodialysis: Comparison of QuantiFERON-TB GOLD, ELISPOT, and Tuberculin Skin Test. <i>Infection</i> , 2009, 37, 96-102.	4.7	85
48	Laparoscopic peritoneal biopsy can be crucial for diagnosis of tuberculous peritonitis. <i>Clinical Journal of Gastroenterology</i> , 2009, 2, 408-411.	0.8	1
49	Performance of the tuberculin skin test and interferon- $\gamma$ release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. <i>BMC Infectious Diseases</i> , 2009, 9, 207.	2.9	77
50	Latent Tuberculosis Infection in Travelers: Is There a Role for Screening Using Interferon- $\gamma$ Release Assays?. <i>Journal of Travel Medicine</i> , 2009, 16, 352-356.	3.0	3
51	Serosorting for hepatitis C status in the sharing of injection equipment among Seattle area injection drug users. <i>Drug and Alcohol Dependence</i> , 2009, 105, 215-220.	3.2	29
52	Biomarkers of latent TB infection. <i>Expert Review of Respiratory Medicine</i> , 2009, 3, 387-401.	2.5	25
53	Annual Incidence of Latent Tuberculosis Infection among Newly Employed Nurses at a Tertiary Care University Hospital. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 1218-1222.	1.8	40
54	Tuberculin Skin Test, Interferon-gamma Assay, and T Cells Subpopulations in Hemodialysis Patients. , 2010, 20, S109-S117.		7
55	New approaches in the diagnosis and treatment of latent tuberculosis infection. <i>Respiratory Research</i> , 2010, 11, 169.	3.6	67
56	Quantiferon test for tuberculosis screening in sarcoidosis patients. <i>Scandinavian Journal of Infectious Diseases</i> , 2011, 43, 728-735.	1.5	20
58	Laboratory Diagnosis of Tuberculosis in Resource-Poor Countries: Challenges and Opportunities. <i>Clinical Microbiology Reviews</i> , 2011, 24, 314-350.	13.6	387

#	ARTICLE	IF	CITATIONS
59	A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor $\alpha$ inhibitor. <i>Clinical Rheumatology</i> , 2011, 30, 505-510.	2.2	19
61	Colon Tuberculosis: Endoscopic Features and Prospective Endoscopic Follow-Up After Anti-Tuberculosis Treatment. <i>Clinical and Translational Gastroenterology</i> , 2012, 3, e24.	2.5	70
62	Tuberculosis of the head and neck: varied clinical presentations and MRI findings. <i>Oral Radiology</i> , 2012, 28, 146-149.	1.9	0
63	Immune markers and correlates of protection for vaccine induced immune responses. <i>Vaccine</i> , 2012, 30, 4907-4920.	3.8	144
64	Interferon-Gamma Release Assays Are a Better Tuberculosis Screening Test for Hemodialysis Patients: A Study and Review of the Literature. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2012, 23, 114-116.	1.9	18
65	The potential for vaccination in leprosy elimination: new tools for targeted interventions. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2012, 107, 190-196.	1.6	14
66	Evaluation of interferon-gamma release assays for the diagnosis of tuberculosis: an updated meta-analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 3127-3137.	2.9	34
67	Utility of QuantiFERON®-TB Gold test in diagnosis and management of suspected tubercular uveitis in India. <i>International Ophthalmology</i> , 2012, 32, 217-223.	1.4	47
68	Evaluation of various cytokines elicited during antigen-specific recall as potential risk indicators for the differential development of leprosy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 1443-1451.	2.9	22
69	The use of methotrexate in dermatology: a review. <i>Australasian Journal of Dermatology</i> , 2012, 53, 1-18.	0.7	84
70	Clinical signs of uveitis associated with latent tuberculosis. <i>Clinical and Experimental Ophthalmology</i> , 2012, 40, 689-696.	2.6	39
71	Screening of Donor and Recipient in Solid Organ Transplantation. <i>American Journal of Transplantation</i> , 2013, 13, 9-21.	4.7	115
72	Factors Influencing Discrepancies Between the QuantiFERON-TB Gold in Tube Test and the Tuberculin Skin Test in Korean Patients with Rheumatic Diseases. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 424-432.	3.4	31
73	Comparison of the tuberculin skin test and Quanti-FERON-TB Gold In-Tube (QFT-G) test for the diagnosis of latent tuberculosis infection in dialysis patients. <i>Journal of Infection and Public Health</i> , 2013, 6, 166-172.	4.1	16
74	Laboratory Methods for Diagnosis and Management of Hepatitis C Virus Infection. <i>Laboratory Medicine</i> , 2013, 44, 292-299.	1.2	9
75	Screening options for tuberculosis. <i>Nurse Practitioner</i> , 2013, 38, 16-18.	0.3	0
76	Indeterminate T-SPOT. $\leq$ TB $\leq$ Test Results in Patients with Suspected Extrapulmonary Tuberculosis in Routine Clinical Practice. <i>Infection and Chemotherapy</i> , 2013, 45, 44.	2.3	21
77	Tuberculin Skin Tests versus Interferon-Gamma Release Assays in Tuberculosis Screening among Immigrant Visa Applicants. <i>Tuberculosis Research and Treatment</i> , 2014, 2014, 1-11.	0.6	4

#	ARTICLE	IF	CITATIONS
78	Tuberculin skin testing in inflammatory bowel disease patients from an endemic area of Brazil. Brazilian Journal of Infectious Diseases, 2014, 18, 60-64.	0.6	6
79	Comparison of Tuberculin Skin Test result and interferon gamma response to human PPD in BCG scar positive and negative children. Journal of Epidemiology and Global Health, 2014, 4, 45.	2.9	6
80	Prospective Head-to-Head Study Comparing 2 Commercial Interferon Gamma Release Assays for theADiagnosis of Tuberculous Uveitis. American Journal of Ophthalmology, 2014, 157, 1306-1314.e4.	3.3	34
81	Prevalence and Treatment of Latent Tuberculosis Infection Among Newly Arrived Refugees in San Diego County, January 2010â€“October 2012. American Journal of Public Health, 2014, 104, e95-e102.	2.7	28
82	A Systematic Review on TST and IGRA Tests Used for Diagnosis of LTBI in Immigrants. Molecular Diagnosis and Therapy, 2015, 19, 9-24.	3.8	50
83	A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection. Applied Health Economics and Health Policy, 2015, 13, 325-340.	2.1	21
84	Latent Tuberculosis Infection Screening in Immigrants to Low-Incidence Countries: A Meta-Analysis. Molecular Diagnosis and Therapy, 2015, 19, 107-117.	3.8	30
85	Evaluation of influenza vaccine-immunogenicity in cell-mediated immunity. Cellular Immunology, 2016, 310, 165-169.	3.0	14
86	Unbiased Identification of Blood-based Biomarkers for Pulmonary Tuberculosis by Modeling and Mining Molecular Interaction Networks. EBioMedicine, 2017, 15, 112-126.	6.1	75
87	Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA. Lancet Infectious Diseases, The, 2017, 17, e327-e333.	9.1	87
88	Tuberculin skin test and interferon-gamma release assay use among privately insured persons in the United States. International Journal of Tuberculosis and Lung Disease, 2017, 21, 684-689.	1.2	4
89	Assessment of the QuantiFERON-TB Gold In-Tube test for the detection of Mycobacterium tuberculosis infection in United States Navy recruits. PLoS ONE, 2017, 12, e0177752.	2.5	11
90	Practical Guidance for Clinical Microbiology Laboratories: Mycobacteria. Clinical Microbiology Reviews, 2018, 31, .	13.6	175
91	Screening of donor and candidate prior to solid organ transplantationâ€™Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13548.	1.6	104
92	Identifying molecularly defined antigens for a Histoplasma capsulatum-specific interferon gamma release assay. Revista Iberoamericana De Micologia, 2019, 36, 186-191.	0.9	2
93	Cost-effectiveness of QuantiFERON-TB Gold In-Tube versus tuberculin skin test for diagnosis and treatment of Latent Tuberculosis Infection in primary health care workers in Brazil. PLoS ONE, 2019, 14, e0225197.	2.5	8
94	Differential T cell responses against DosR-associated antigen Rv2028c in BCG-vaccinated populations with tuberculosis infection. Journal of Infection, 2019, 78, 275-280.	3.3	6
95	An interferon gamma release assay specific for Histoplasma capsulatum to detect asymptomatic infected individuals: A proof of concept study. Medical Mycology, 2019, 57, 724-732.	0.7	13

#	ARTICLE	IF	CITATIONS
96	Bacterial Diseases. , 2019, , 265-287.		6
97	Comparison of tuberculin skin test and interferon gamma release assay in pediatric candidates of heart transplantation and a 2â€year followâ€up. Transplant Infectious Disease, 2020, 22, e13268.	1.7	0
98	Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1. MSphere, 2020, 5, .	2.9	8
99	Role of interferon gamma release assay in the diagnosis and management of Mycobacterium tuberculosis-associated uveitis: a review. BMJ Open Ophthalmology, 2021, 6, e000663.	1.6	9
100	Latent tuberculosis infection among patients with and without type-2 diabetes mellitus: results from a hospital case-control study in Atlanta. BMC Research Notes, 2021, 14, 252.	1.4	8
101	A review of the leishmanin skin test: A neglected test for a neglected disease. PLoS Neglected Tropical Diseases, 2021, 15, e0009531.	3.0	22
102	Intestinal tuberculosis and Crohn's disease: the dilemma of similarities and misdiagnosis. BMJ Case Reports, 2009, 2009, bcr0420091729-bcr0420091729.	0.5	5
103	Comparison of Mantoux and Tine Tuberculin Skin Tests in BCG-Vaccinated Children Investigated for Tuberculosis. PLoS ONE, 2009, 4, e8085.	2.5	9
104	Poor agreement between QuantiFERON-TB Gold test and tuberculin skin test results for the diagnosis of latent tuberculosis infection in rheumatoid arthritis patients and healthy controls. Korean Journal of Internal Medicine, 2014, 29, 76.	1.7	11
105	Predictive value of the tuberculin skin test and QuantiFERON-tuberculosis Gold In-Tube test for development of active tuberculosis in hemodialysis patients. Annals of Thoracic Medicine, 2016, 11, 114.	1.8	10
106	Prevention and Treatment of Infection in Kidney Transplant Recipients. , 2008, , 1034-1046.		1
107	Infectious Complications in Renal Transplant Recipients. , 2012, , 179-210.		0
108	Post-Travel Screening. , 2013, , 467-474.		1
109	Hepatitis B and C Viruses. , 2016, , 641-657.		0
110	Tuberculin Skin Test and Interferon-Î³ Release Assays in the Diagnosis of Ocular Tuberculosis. Essentials in Ophthalmology, 2017, , 35-49.	0.1	0
111	Ocular Tuberculosis in Immunocompromised Patients. Essentials in Ophthalmology, 2017, , 101-110.	0.1	1
113	Tuberculosis 2004: challenges and opportunities. Transactions of the American Clinical and Climatological Association, 2005, 116, 293-308; discussion 308-10.	0.5	2
114	Aqueous cytokine and chemokine analysis in uveitis associated with tuberculosis. Molecular Vision, 2012, 18, 565-73.	1.1	40

#	ARTICLE	IF	CITATIONS
115	Management of newborn infant born to mother suffering from tuberculosis: current recommendations & gaps in knowledge. Indian Journal of Medical Research, 2014, 140, 32-9.	1.0	15
116	Smear grading and the Mantoux skin test can be used to predict sputum smear conversion in patients suffering from tuberculosis. GMS Hygiene and Infection Control, 2017, 12, Doc12.	0.3	2
117	Update of the mechanism and characteristics of tuberculosis in chronic kidney disease. Wiener Klinische Wochenschrift, 2022, 134, 501-510.	1.9	1